June 2026 Research Update

At a glance

Delayed symptoms

Symptoms often began months after immunotherapy started.

Common management

Reports often described stopping immunotherapy and using steroids.

Reported improvement

About two-thirds had partial or complete symptom improvement.

Monthly takeaway

Reports described eosinophilic fasciitis starting later after immunotherapy and often improving. These case reports do not show which treatment works best.

Overview

This month, the main new information was about eosinophilic fasciitis that happens after immune checkpoint inhibitor cancer immunotherapy.

Across a collected set of 121 reported cases, eosinophilic fasciitis often started months after immunotherapy began. The typical time to onset was about 10 months. This helps explain why symptoms that begin later in a treatment course can still fit this pattern.

The most commonly reported management steps were stopping the immune checkpoint inhibitor and using systemic corticosteroids. Some people also received other immune-suppressing medicines.

In these reported cases, about two-thirds of patients had partial or complete resolution. This suggests improvement was common in routine care reports, but it did not happen for everyone.

Research topics this month

Limitations

• Findings come from a retrospective collection of reported cases, not a randomized treatment trial.
• Case reports and collections can miss details, so outcomes and timing may not be fully consistent.
• The evidence describes patterns and typical care steps, but cannot show which specific approach works best.

Important information

• This document summarizes recent research from PubMed-indexed publications using automated methods.
• It is intended for educational purposes and does not replace medical advice.
• Links to the original studies are provided via PubMed, where readers can explore abstracts and, when available, access full-text articles.
• Some studies may include additional details that were not accessible for this summary.
• Readers seeking more complete detail or context may find it helpful to review the original studies directly.

1. 1.Bruijn TVM, Gérard AO, Labat M, Apalla Z, Binsbergen WV, Koumaki D, Rivet V, Dezoteux F, Giacchero D, Ardern-Jones MR, Heelan K, Hirner JP, Mayor A, Labots M, Starink MV, Laken CJV, Sibaud V, Elshot YS. Immune checkpoint inhibitor-induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study. J Eur Acad Dermatol Venereol (2026). Open in new tab